BAX · CIK 0000010456 · operating
Baxter International operates across three primary business segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The company manufactures sterile intravenous solutions, infusion systems and devices, parenteral nutrition therapies, and respiratory health devices. Its product portfolio also includes inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostats and sealants, advanced surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and operating room integration systems.
The company's customer base spans hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, physician offices, kidney dialysis centers, and home-care settings. Baxter distributes its products through a combination of direct sales personnel, independent distributors, drug wholesalers, and specialty pharmacy providers across North America, Western Europe, Eastern Europe, the Middle East, Africa, Latin America, Asia, Japan, Australia, and New Zealand.
With approximately 37,500 full-time employees, Baxter operates as a diversified medical device and pharmaceutical manufacturer. The company was incorporated in Delaware in 1931 and maintains its headquarters in Deerfield, Illinois. Its geographic footprint and multi-segment structure position it to serve institutional and home-based healthcare settings across developed and emerging markets.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.87 | $-1.87 | -87.0% | |
| 2024 | $-1.00 | $-1.00 | -308.3% | |
| 2023 | $0.48 | $0.48 | +109.9% | |
| 2022 | $-4.83 | $-4.83 | -290.9% | |
| 2021 | $2.53 | $2.56 | +666.7% | |
| 2020 | $0.33 | $0.33 | +760.0% | |
| 2019 | $-0.05 | $-0.05 | -107.7% | |
| 2018 | $0.65 | $0.66 | +600.0% | |
| 2017 | $-0.13 | $-0.13 | -129.5% | |
| 2016 | $0.44 | $0.45 | +18.9% | |
| 2015 | $0.37 | $0.37 | -78.7% | |
| 2014 | $1.74 | $1.76 | +194.9% | |
| 2013 | $0.59 | $0.60 | -33.7% | |
| 2012 | $0.89 | $0.90 | +8.5% | |
| 2011 | $0.82 | $0.82 | -65.7% | |
| 2010 | $2.39 | $2.41 | -33.4% | |
| 2009 | $3.59 | $3.63 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-12 | 0001628280-26-007733 | SEC ↗ |
| 2024-12-31 | 2025-02-21 | 0001628280-25-007201 | SEC ↗ |
| 2023-12-31 | 2024-02-08 | 0001628280-24-003932 | SEC ↗ |
| 2022-12-31 | 2023-02-09 | 0001628280-23-002864 | SEC ↗ |
| 2021-12-31 | 2022-02-23 | 0001628280-22-003432 | SEC ↗ |
| 2020-12-31 | 2021-02-11 | 0001628280-21-001867 | SEC ↗ |
| 2019-12-31 | 2020-03-17 | 0001628280-20-003693 | SEC ↗ |
| 2018-12-31 | 2019-02-21 | 0001564590-19-003727 | SEC ↗ |
| 2017-12-31 | 2018-02-23 | 0001564590-18-002954 | SEC ↗ |
| 2016-12-31 | 2017-02-23 | 0001564590-17-002240 | SEC ↗ |
| 2015-12-31 | 2016-02-26 | 0001193125-16-479471 | SEC ↗ |